Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs

Prostate

Volumn 68, Issue 2, 2008, Pages 171-182

  Rovenská, Miroslava ^a,b   Hlouchová, Klára ^a,b   Šácha, Pavel ^a,b   Mlčochová, Petra ^a,b   Horák, Vratislav ^c   Zámečník, Josef ^d   Bařinka, Cyril ^a,e   Konvalinka, Jan ^a,b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Animal model; Animal orthologs; Glutamate carboxypeptidase II; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GCP 04; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER THERAPY; DIAGNOSTIC VALUE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOENZYMATIC ASSAY; RAT; SOLID TUMOR; SWINE; TESTIS; TISSUE DISTRIBUTION; TREATMENT PLANNING; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KIDNEY; MALE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RATS; RATS, INBRED LEW; SPECIES SPECIFICITY; SPINAL CORD; SWINE; SWINE, MINIATURE; TESTIS;

EID: 38749134876     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20676     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Davis MI, Bennet MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102:5981-5986.
3. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006;25:1375-1384.
4. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
5. Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the brain dipeptide N-aceryl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated-alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987;262:14498-14506.
6. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-1443.
7. Schmittgen TD, Teske S, Vessela RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003;107:323-329.
8. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-4789.
9. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-636.
10. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
11. Chang SS, ÓKeefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
12. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
13. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7 E11-C5. Cancer Res 1990;50: 6423-6429.
14. Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdel-Nabi H, Winzelberg G. Immunoscintigraphy of prostatic cancer: Preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-241.
15. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate 1998;37:261-269.
16. Bander NH. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006;3:216-225.
17. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy GP. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996; 28:65-69.
18. Murphy GP, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
19. Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49:117-128.
20. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9-23.
21. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-2531.
22. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-4601.
23. Bzdega T, Turi T, Wroblewska B, She D, Chung HS, Kim H, Neale JH. Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem 1997;69:2270-2277.
24. Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 1998;95:3215-3220.
25. Halsted CH, Ling E, Luthi-Carter R, Villanueva JA, Gardner J, Coyle JT. Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem 1998;273:20417-20424.
26. Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002;80:477-487.
27. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007;144:1361-1372.
28. Horak V, Fortyn K, Hruban V, Klaudy J. Hereditary melanoblastoma in miniature pigs and its successful therapy by devitalization technique. Cell Mol Biol 1999;45:1119-1129.
29. Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004;13:1627-1635.
30. Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 1996;39:619-622.
31. Slusher BS, Vornov JJ, Thomas AG, Hum PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, Tortella FC, Wozniak KM, Yudkoff M, Potter BM, Jackson PF. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999;5:1396-1402.
32. Zhang W, Slusher BS, Murakawa Y, Wozniak KM, Tsukamoto T, Jackson PF, Sima AA. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002;194:21-28.
33. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26:5310-5324.
34. Slusher BS, Robinson MB, Guochuan T, Simmons ML, Richards SS, Coyle JT. Rat brain N-acetylated α-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 1990;265:21297-22301.
35. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998; 286:1020-1025.
36. Bařinka C, Rovenská M, Mlčochová P, Hlouchová K, Plechanovová A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 2007;50: 3267-3273.
37. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807-1811.
38. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229-238.
39. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization and enzymatic activities of the mouse homologue of prostate-specific membrane antigen/NAALA-Dase/folate hydrolase. Mamm Genome 2001;12:117-123.
40. Aggarwal S, Ricklis RM, Williams SA, Denmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate 2006;66:903-910.
41. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
42. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000;43:150-157.
43. Renneberg H, Friedetzky A, Konrad L, Kurek R, Weingartner K, Wennemuth G, Tunn UW, Aumuller G. Prostate specific membrane antigen (PSM) is expressed in various human tissues: Implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer speed. Urol Res 1999;27:23-27.
44. Lucia MS, Bostwick DG, Bosland M, Cockett ATK, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: Rodent models of prostate cancer. Prostate 1998; 36:49-55.
45. Shafizadeh TB, Halsted CH. γ-glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 2007;137:1149-1153.
46. Pangalos MN, Neefs JM, Somers M, Verhasselt P, Bekkers M, van der Helm L, Fraiponts E, Ashton D, Gordon RD. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem 1999;274:8470-8483.
47. Lambert LA, Mitchell SL. Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family. J Mol Evol 2007; 64:113-128.
48. Hlouchova K, Barinka C, Klusak V, Sacha P, Mlcochova P, Majer P, Rulisek L, Konvalinka J. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 2007;101: 682-696.